Porownywarka

Veslugen vs Livagen side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

VeslugenLivagen

Udostępnij porównanie peptydów

Wlasciwosc	Veslugen	Livagen
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	Vesugen, KED	Lys-Glu-Asp-Ala, KEDA
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Preclinical research; reported as approved in Russia as a supplement Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical research; reported as approved in Russia as a supplement Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Circulatory health, vascular support, aging	Gene expression, cellular aging, liver health
Jak dziala	Veslugen/KED is proposed to act through gene-regulatory effects rather than a conventional receptor target. The cited source describes a hypothesis in which the short peptide enters cells, localizes near nuclear DNA, and changes promoter activity linked to vascular biology. Reported mechanistic work includes molecular docking near MKI67 and experimental observations involving endothelial markers such as endothelin-1, connexins, sirtuin-1, and nitric oxide. The evidence described is largely computational, in vitro, animal-based, and concentrated within one research lineage.	Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.
Typowe dawkowanie	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual
Dawkowanie z badań	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typowy czas trwania	10-30 day cycles	10-30 day cycles
Podanie	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning on an empty stomach Take on an empty stomach	Morning on an empty stomach Take on an empty stomach
Poziom dowodów	Przedkliniczne	Przedkliniczne
Mozliwe skutki uboczne	Generally well tolerated (Reported by the source, but formal safety data are limited.) Limited safety data outside Russia (The source notes limited external safety evidence beyond the Russian context.) Not FDA approved (This is a regulatory limitation rather than a physiological adverse effect.)	Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.) Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.) Not FDA approved (This is regulatory status, not an adverse effect.)
Podsumowanie researchu	The source describes KED as a defined ultrashort peptide discussed in peer-reviewed Khavinson-related literature, including review material that mentions vascular and blood-brain-barrier biology in cell and animal contexts. Reported findings include gene-expression changes, nitric oxide stimulation, and normalization of endothelial markers, but the source characterizes the evidence as mostly in vitro, molecular docking, and aged-animal work. Human evidence is described as very limited and not based on rigorous placebo-controlled trials, with little independent replication outside the originating research group.	The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.
Referencje	Peptibase peptides Peptibase peptides +2 więcej Peptibase peptides Peptibase peptides	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Veslugen

Livagen

Kategoria

Bioregulatory

Znany tez jako

Vesugen, KED

Lys-Glu-Asp-Ala, KEDA

Zatwierdzony przez FDA

Nie

Status kliniczny

Preclinical research; reported as approved in Russia as a supplement

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical research; reported as approved in Russia as a supplement

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Circulatory health, vascular support, aging

Gene expression, cellular aging, liver health

Jak dziala

Veslugen/KED is proposed to act through gene-regulatory effects rather than a conventional receptor target. The cited source describes a hypothesis in which the short peptide enters cells, localizes near nuclear DNA, and changes promoter activity linked to vascular biology. Reported mechanistic work includes molecular docking near MKI67 and experimental observations involving endothelial markers such as endothelin-1, connexins, sirtuin-1, and nitric oxide. The evidence described is largely computational, in vitro, animal-based, and concentrated within one research lineage.

Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.

Typowe dawkowanie

10-20 mg daily · Once or twice daily

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual

Dawkowanie z badań

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typowy czas trwania

10-30 day cycles

Podanie

Oral capsules or sublingual

Timing

Morning on an empty stomach

Take on an empty stomach

Morning on an empty stomach

Take on an empty stomach

Poziom dowodów

Przedkliniczne

Mozliwe skutki uboczne

Generally well tolerated (Reported by the source, but formal safety data are limited.)
Limited safety data outside Russia (The source notes limited external safety evidence beyond the Russian context.)
Not FDA approved (This is a regulatory limitation rather than a physiological adverse effect.)

Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.)
Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.)
Not FDA approved (This is regulatory status, not an adverse effect.)

Podsumowanie researchu

The source describes KED as a defined ultrashort peptide discussed in peer-reviewed Khavinson-related literature, including review material that mentions vascular and blood-brain-barrier biology in cell and animal contexts. Reported findings include gene-expression changes, nitric oxide stimulation, and normalization of endothelial markers, but the source characterizes the evidence as mostly in vitro, molecular docking, and aged-animal work. Human evidence is described as very limited and not based on rigorous placebo-controlled trials, with little independent replication outside the originating research group.

The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.

Referencje

Peptibase peptides Peptibase peptides

+2 więcej

Peptibase peptides Peptibase peptides

Źródło Źródło

+2 więcej

Źródło Źródło

Pełny profil

Zobacz szczegóły